SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences to present its investigational neuroscience NCEs at AAIC

17 Jul 2015 Evaluate

Several exciting new results and data presentations from Suven Life Science’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Alzheimer's Association International Conference (AAIC) being held in Washington DC, USA during July 18-23, 2015. AAIC is the world's largest conference of its kind, where thousands of researchers from more than 70 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.

Alzheimer’s disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills. Alzheimer’s is the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression.

Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer’s disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×